Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GABRP | O00591 | 1/20 | 0.32 |
| ▸ | GABRD | O14764 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.32 |
| ▸ | GABRE | P78334 | 1/20 | 0.32 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29993398 | 1.00 | TDP1 (0.41) | TDP1NOS3NOS1NOS2SMN1; SMN2 | |
| SCHEMBL2877727 | 0.79 | TLR8 (0.47) | — | |
| SCHEMBL29404355 | 0.77 | TDP1 (0.44) | TDP1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1188816 | 0.77 | TDP1 (0.44) | TDP1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL2259889 | 0.76 | TDP1 (0.33) | TDP1NOS3NOS1NOS2GRIN2D | |
| SCHEMBL3966501 | 0.76 | NOS3 (0.41) | NOS3NOS1NOS2KMT2AKDM4E | |
| SCHEMBL1188542 | 0.74 | ALDH1A1 (0.35) | TDP1ALDH1A1 | |
| SCHEMBL1566107 | 0.74 | TDP1 (0.34) | TDP1SMN1; SMN2HTT | |
| SCHEMBL22044740 | 0.71 | GABRP (0.44) | NOS3NOS1NOS2SMN1; SMN2KMT2A | |
| SCHEMBL19704108 | 0.71 | SMN1; SMN2 (0.38) | TDP1NOS3NOS1NOS2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240409536-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2024-12-12 | — | — | US | disclosed |
| EP-4395891-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Remix Therapeutics Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-118234724-A | Compounds and methods for modulating splicing | 雷密克斯医疗公司 | 2024-06-21 | — | — | CN | disclosed |
| WO-2023034811-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| WO-2023034811-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| EP-3887372-B1 | FURTHER HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2022-10-12 | — | — | EP | disclosed |
| US-20220033396-A1 | FURTHER HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV | Janssen Sciences Ireland Unlimited Company (IE) | 2022-02-03 | — | — | US | disclosed |
| EP-3887372-A1 | FURTHER HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV | Janssen Sciences Ireland Unlimited Company (IE) | 2021-10-06 | — | — | EP | disclosed |
| CN-113166146-A | Other heteroaromatic compounds with anti-RSV activity | 爱尔兰詹森科学公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020109224-A1 | FURTHER HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV | Janssen Sciences Ireland Unlimited Company (IE) | 2020-06-04 | — | — | WO | disclosed |
| WO-2020109224-A1 | FURTHER HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV | Janssen Sciences Ireland Unlimited Company (IE) | 2020-06-04 | — | — | WO | disclosed |
| EP-1928879-B1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2013-02-13 | — | — | EP | disclosed |
| CN-101312977-B | Fused heterocyclic compounds useful as kinase modulators | BRISTOL MYERS SQUIBB CO | 2012-06-13 | — | — | CN | disclosed |
| US-20100204212-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-12 | — | — | US | disclosed |
| US-7723336-B2 | Fused heterocyclic compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-25 | — | — | US | disclosed |
| CN-101312977-A | Fused heterocyclic compounds useful as kinase modulators | BRISTOL MYERS SQUIBB CO (US) | 2008-11-26 | — | — | CN | disclosed |
| EP-1928879-A2 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | Brystol-Myers Squibb Company (US) | 2008-06-11 | — | — | EP | disclosed |
| US-20080045536-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| WO-2007038314-A2 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-05 | — | — | WO | disclosed |
| US-20070078136-A1 | Fused heterocyclic compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409536-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | TDP1 406/4885NOS3 1216/4885NOS1 1941/4885 |
| US-20070078136-A1 | Fused heterocyclic compounds useful as kinase modulators | MAP3K2, MAP3K3, MAP4K2 | TDP1 3932/4885NOS3 1050/4885NOS1 1913/4885 |
| US-20100204212-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | MAP2K2, MAP3K2, MAP4K2 | TDP1 3630/4885NOS3 1612/4885NOS1 1894/4885 |
| US-20220033396-A1 | FURTHER HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV | VIM, MAVS, VARS1 | TDP1 3917/4885NOS3 2058/4885NOS1 2122/4885 |
| US-20080045536-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | MAP3K3, MAP3K2, MAP4K3 | TDP1 3883/4885NOS3 915/4885NOS1 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.